BSP Medical Ltd.是一家来自于以色列的创新型生物医疗公司，扎根心血管领域研究三十余年，是全球高频 QRS 技术领域绝对领军企业。其核心产品HyperQ全息数字心脏检测技术，是全球首家获得 FDA/CE/NMPA 许可， 提前 48 小时-720 天心梗猝死精准诊断及预警系统，也是能定性、定量、定位、定型诊断心梗猝死的颠覆性技术，更是全球心梗精准诊疗的推动者。HyperQ技术，有望将临床心梗漏诊率降低到10%以内，为全球用户的心血管健康保驾护航。

Hong Kong based Elleon Biotech present “PhenoDot” our patent pending system which
encapsulates cells creating visible dots allowing detection, quantification, and isolation of
cells by surface and secretion markers in one assay. PhenoDot combines many strengths of
FACs and ELISpot into a single assay whilst maintaining cell viability with single cell
resolution

Hitachi is a global leading life science facility provider with IoT ready solutions. Modular type Cell Processing Facility (CPF) is able to reduce initial setup cost with shorten 50% of conventional ducting design. The modular CPF is easy to be expand and relocated to other building without duplicated investment. Hitachi’s unique design Fan Filter Unit (FFU) is able to realize 15%-20% energy saving as well as fitting for most of buildings with headroom over 2.6-meter height.
By using the latest digital solution of MES, the production data and operation data are integrated into data-lake for remote monitoring and able to support new continuous improvements in quality and new application pipelines.
Hitachi also provide GMP/non-GMP facilities under PIC/S standard. Additions to hardware and software, our expert team provide GMP consultation services and MES in cell therapies and pharmaceutical manufacturing. Our excellence industry experiences and business networks are able to solve pain points and challenges for our client worldwide.

The Hong Kong Council for Testing and Certification (HKCTC) was established in September 2009 to advise the Government on the overall development strategy of the testing and certification sector. Members of the Council include practitioners from the testing and certification sector, business sector, professional organisations as well as the relevant public bodies and government departments. The Innovation and Technology Commission provides support to the Council.

Insilico Medicine Hong Kong Limited

Intellectual Property Department was established on 2 July 1990. The Department took over from the Registrar General’s Department the responsibility for the registration of patents and trade marks for goods and for other related matters. The Director of Intellectual Property replaced the Registrar General as the Registrar of Trade Marks and Registrar of Patents. The Department also took over functions relating to copyright from the Attorney General’s Department. In 1998, the Department also became the Government’s civil legal advisor on intellectual property legal matters.

Lee’s Pharm is a public biopharmaceutical company with over 25 years of operation in China’s pharmaceutical industry. We are committed to the research and development of innovative products to address unmet medical needs and improve patients’ quality of l

OPIS is a full-service Contract Research Organization (CRO) founded in 1998 in Italy, providing premium trial management for multi-country clinical trials, including state-of-the-art information technology solutions and innovative approaches to the increasing complexity and variety of current projects. OPIS extensive expertise can cover all phases of drug related trials, with no restrictions to therapeutic area as well as clinical investigations for medical and diagnostic devices, Investigator Initiated Trials (IITs), and compassionate use programs.

At Provectus Therapeutics, we are committed to transforming the landscape of personalised oncology treatments through innovative research and development. Our strategic investments and robust R&D initiatives have positioned us at the forefront of cancer research advancements.

Rieckermann Pharmatech have a wide service portfolio that covers the whole lifecycle of industrial projects, including consulting, engineering, contracting, the sourcing of machinery and equipment, shipping, installation, after sales services and consumables supply.

Zhaoke Ophthalmology is focusing on advancing towards the goal of product commercialisation, and achieve the objective of improving visual health in China through scientific research as soon as possible.

“凯斯艾生物科技（苏州）有限公司及其旗下全资子公司江苏珂玛麒生物科技有限公司，致力于为全球制药企业和科研机构提供全方位临床前新药研发服务，建立专业高效的药物研发评价体系。凯斯艾·珂玛麒拥有苏州、南通两个国际先进水平的实验动物设施，均获得国际AAALAC认证，
总面积超过18000㎡；已建立起包括大小鼠、仓鼠、豚鼠、兔、猫、犬、猪、雪貂及非人灵长类的全品类实验动物平台、肿瘤及非肿瘤疾病动物模型400余种、ABSL-2/BSL-2抗感染药物与疫苗评价实验平台、病理学、细胞与分子生物学、药代动力学、医学影像学等多个研究服务平台。”

昭衍新药（股份代码：603127.SH/6127.HK）是中国最早从事药物非临床评价的CRO企业，1995年成立至今，已拥有近3000人的专业技术团队。昭衍新药拥有符合国际规范的质量管理体系（CNAS/ILAC-MRA认证），具备中国NMPA、美国FDA、经合组织OECD、韩国MFDS、日本PMDA的GLP资质以及国际AAALAC（动物福利）认证资质，评价资料满足全球药品注册要求。可以向客户提供非临床药理毒理学研究及评价，特别是非临床安全性评价，临床试验及药物警戒等一站式服务；还可以提供兽药、农药及医疗器械评价等服务项目。在北京、苏州、重庆、广州、上海、梧州、南宁、云南以及美国加州、波士顿设有子公司。
昭衍秉承“服务药物创新，专注于药物全生命周期的安全性评价和监测”的宗旨，保障患者用药安全，呵护人类健康！

杭州中赢生物医疗科技有限公司是杭州国家高新区（滨江)重点支持的海外高层次专家团队联合创办的高新技术企业，系国内较早一家立足于再生医学、专注免疫细胞存储与应用，集研发、生产、营销为一体的高新技术企业。公司主要从事免疫细胞，特别是NK类细胞在体外的大规模制备试剂的开发。作为国内最早的免疫细胞研究企业之一，中赢生物拥有发明专利55余项，其中已获国家知识产权局授权发明专利30项，凭借先进技术确保了行业内的领先位置。公司先后入选了杭州市企业高新技术研发中心、国家高新技术企业、杭州市专利示范企业、瞪羚企业，首批“杭州区域细胞制备中心”试点企业、浙江省“专精特新”中小企业，主导起草的《自然杀伤细胞（NK）扩增试剂》“浙江制造”标准已发布。2024年，参与起草的国家标准《生物技术 基本术语》已完成征求意见的收集和审查，现由中国标准化研究院提报国家市场监督管理总局批准，预计年底可发布实施。

深圳灵赋拓普生物科技有限公司（简称灵赋拓普）成立于 2015 年，是一家专注动物科研，服务临床前研究与评价的创新型 CRO 企业。公司以动物模型为核心，同时开展细胞、病理、蛋白、分子、生化、行为学等一站式服务，赋能生命科学和生物医药研究。